Elutia Inc (ELUT) FinancialsELUTElutia Inc

Elutia Inc (ELUT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Core Products, accounting for 72.2% of total sales, equivalent to $8.95M. Another important revenue stream is NonCore Products. Understanding this composition is critical for investors evaluating how ELUT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Elutia Inc maintains a gross margin of 59.62%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -243.10%, while the net margin is -315.04%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ELUT converts its operational activities into shareholder value.

In the context of the broader market, ELUT competes directly with industry leaders such as BCTX and ZYBT. With a market capitalization of $37.43M, it holds a significant position in the sector. When comparing efficiency, ELUT's gross margin of 59.62% stands against BCTX's N/A and ZYBT's 20.51%. Such benchmarking helps identify whether Elutia Inc is trading at a premium or discount relative to its financial performance.

Elutia reported a gross margin of 59.62% in Q2 2026, which is an improvement from previous quarters, indicating better cost management. However, the company has faced significant net losses, with a reported loss of $7.6 million in Q2 2026, raising concerns about profitability.